EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach

Daichi Yamaguchi iD, Takayuki Katsube, Toshihiro Wajima

Pharmacology Research & Perspectives · 2024

DOI: 10.1002/prp2.70001 ↗

At a glance

Journal article in Pharmacology Research & Perspectives, 2024. Written by Daichi Yamaguchi and 2 co-authors. Institution: Clinical Pharmacology & Pharmacokinetics, Shionogi & Co., Ltd., Osaka, Japan. Major MEDLINE topics: Cephalosporins, Anti-Bacterial Agents, Cefiderocol. Cited 1 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Shionogi.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

When planning pediatric clinical trials, optimizing the sample size of neonates/infants is essential because it is difficult to enroll these subjects. In this simulation study, we evaluated the sample size of neonates/infants using a model‐based optimal approach for identifying their pharmacokinetics for cefiderocol. We assessed the usefulness of data for estimation performance (accuracy and variance of parameter estimation) from adults and the impact of data from very young subjects, including preterm neonates. Stochastic simulation and estimation were utilized to assess the impact of sample size allocation for age categories in estimation performance for population pharmacokinetic parameters in pediatrics. The inclusion of adult pharmacokinetic information improved the estimation performance of population pharmacokinetic parameters as the coefficient of variation (CV) range of parameter estimation decreased from 4.9%–593.7% to 2.3%–17.3%. When sample size allocation was based on the age groups of gestational age and postnatal age, the data showed 15 neonates/infants would be necessary to appropriately estimate pediatric pharmacokinetic parameters (

Subjects

MeSH terms (MEDLINE)

CephalosporinsAnti-Bacterial AgentsCefiderocolHumansInfant, NewbornSample SizeInfantModels, BiologicalClinical Trials as TopicComputer SimulationAdultGestational AgeAge Factors

Author keywords

cefiderocolneonates and infantsoptimal designpopulation pharmacokineticsstochastic simulation and estimation

Substances

CephalosporinsAnti-Bacterial AgentsCefiderocol

Authors and institutions

  • Clinical Pharmacology & Pharmacokinetics, Shionogi & Co., Ltd., Osaka, Japan.
  • Pharmacokinetics/Pharmacodynamics & Pharmacometrics, Japan Drug Development & Medical Affairs, Eli Lilly Japan K.K, Kobe, Japan.

ORCID profiles: Daichi Yamaguchi

Funding

  • Shionogi

Cite

APA

Yamaguchi, D., Katsube, T., & Wajima, T. (2024). Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70001

Vancouver

Yamaguchi D, Katsube T, Wajima T. Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach. Pharmacology Research & Perspectives. 2024. doi:10.1002/prp2.70001

BibTeX
@article{Yamaguchi2024,
  author = {Yamaguchi, Daichi and Katsube, Takayuki and Wajima, Toshihiro},
  title = {Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach},
  journal = {Pharmacology Research & Perspectives},
  year = {2024},
  doi = {10.1002/prp2.70001}
}
Start for free →